- Developed by Fermion, FZ002-037 is an oral somatostatin receptor 4 (SSTR4) agonist. Under the terms of the agreement, Simcere will obtain exclusive rights for developing and commercialising the drug The post Fermion and Simcere to...
- This funding round was led by J2 Ventures and the Global Health Investment Corporation (GHIC). With this funding, the company’s total Series A equity value raised to over The post Micron Biomedical secures funds for needle-free vaccine...
- The company is set to launch a multicentre Phase I trial in the US in the first quarter of this year. Axcynsis Therapeutics CEO Dr Zou Bin said: The post FDA clears Axcynsis’ AT03-65 IND for CLDN6-positive solid tumours appeared first on...
- BAFIERTAM will join TASCENSO ODT (fingolimod), Cycle’s other branded MS treatment. Both these therapies will be supported by Cycle’s hub programme, Cycle Vita. The company noted that, during The post Cycle expands MS treatment...
- Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast...
- A new study in Nature by last year's Nobel Laureate in Chemistry reveals a possible game-changer in snakebite treatment. Researchers have created new proteins that neutralise lethal toxins found in snake venom, potentially offering a...
- This designation is for Carteyva, an anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy, as a second-line treatment for adults with this disease. It is developed independently The post JW Therapeutics’ Carteyva...
- With antibiotic resistance a growing problem, University of Virginia School of Medicine researchers have developed cutting-edge computer models that could give the disease-fighting drugs a laser-like precision to target only specific...
- Scientists at the University of Stuttgart have succeeded in controlling the structure and function of biological membranes with the help of "DNA origami". The system they developed may facilitate the transportation of large therapeutic...
- Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center identified a cocktail of three different drugs that can be used to generate more robust immune system CAR-Ts (chimeric antigen...
- SPRIM Global Investments and William Taylor Nominees jointly led the funding round, which will support the conduct of a Phase I trial of RheumaGen’s lead candidate, RG0401. Anticipated The post RheumaGen secures $15m in Series A funding...
- Researchers from POSTECH and Kyungpook National University have developed a novel inhalable therapeutic delivery system for lung cancer, leveraging mucoadhesive protein nanoparticles inspired by the adhesive properties of marine mussels....
- The decision is intended for individuals with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), as assessed by an FDA-approved test. This marks offering a new The post FDA grants priority review to...
- The ‘fully human’, immunoglobulin G4 (IgG4) antibody is tailored to target Protein S, aiming to restore balance in blood clotting and potentially serves as a ‘universal haemostatic therapy’ The post Star Therapeutics’ von...
- PVT401 is said to be the second autoimmune drug candidate from Parvus. Parvus is focused on developing peptide-major histocompatibility complex (pMHC) nanomedicine drugs. These assets can activate in The post Parvus and Resilience expand...
- Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular dystrophy with the help of gene-editing. Preclinical research led by the Spuler Lab published in Nature...
- A varied diet rich in vegetables is known to be healthy for one's well-being. Excessive consumption of meat, especially red meat, can lead to chronic and cardiovascular diseases. That is also because what we eat shapes the gut...
- A new study from researchers at the Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy at Tufts University, which published in Nature Medicine on January 6, estimates that 2.2 million new cases of type 2 diabetes...
- This marks the first NMPA-approved monoclonal antibody that targets gastric tumour cells expressing the biomarker CLDN18.2. The approval offers a new, highly targeted treatment option for individuals particularly The post China’s...
- Introducing Annotatability - a powerful new framework to address a major challenge in biological research by examining how artificial neural networks learn to label genomic data. Genomic datasets often contain vast amounts of annotated...
- Rice University bioengineers have developed a new construction kit for building custom sense-and-respond circuits in human cells. The research, published in the journal Science, represents a major breakthrough in the field of synthetic...
- A new study by investigators from Mass General Brigham uncovers how a novel immunotherapy prevents squamous cell carcinoma, with benefits lasting five years after treatment. This therapy is the first to activate specific components of...
- The standard medication levodopa does not always work against tremors in Parkinson's disease, especially in stressful situations. Propranolol, however, does work during stress, providing insight into the role of the stress system in...
- A drug recently approved to prevent migraine may start working right away, according to a study published in the December 23, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study looked at...
- In a new analysis of data from more than a dozen studies, coffee and tea consumption was linked with lower risks of developing head and neck cancers, including cancers of the mouth and throat. Cancers of the head and neck are the seventh...
- For roughly a century, ever since Alexander Fleming's accidental discovery of penicillin in 1928, fungi have proven to be a goldmine for medicines. They've provided treatments for a wide range of diseases, from infections and high...
- Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the Vanderbilt University School of Medicine Basic Sciences, have detailed the successful drug discovery of a phase I single ascending dose...
- Millions of people take metformin, a Type 2 diabetes medication that lowers blood sugar. The "wonder drug" has also been shown to slow cancer growth, improve COVID outcomes and reduce inflammation. But until now, scientists have been...
- A team of University of Melbourne researchers from the Caruso Nanoengineering Group has created an innovative drug delivery system with outstanding potential to improve drug development. The team has pioneered a drug delivery system that...
- A novel drug holds promise for treating Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes severe muscle degeneration. McGill University researchers have discovered that an experimental compound called K884 can boost...
- The inflammatory disease affects around one in 2,000 people in the US
- Results from a mid-stage of the candidate were recently published in the NEJM
- The skin disease affects an estimated 1% of the population in most studied countries
- The collaboration will first focus on developing products for long COVID and ME/CFS
- Researchers used a technique to identify specific molecular details of biotin-labelled proteins
- Around 60,000 people are diagnosed with pancreatic adenocarcinoma in the US every year
- The company gained access to the drug through its $7.3bn acquisition of Reata Pharmaceuticals
- The drug could prevent conditions including diabetic eye and kidney disease in diabetes
- The Yellow Card Biobank will begin investigating direct oral anticoagulants such as apixaban
- The deal gives the company access to a candidate being evaluated in primary biliary cholangitis
- There are now more than 8,000 patients who are potentially eligible for treatment with Casgevy
- Approximately one in 10,000 people are affected by the genetic blood clotting disorder
- The rare genetic disorder is estimated to affect around one in every 40,000 people in the UK
- F404 mutations combined with pre-existing mutations caused resistance to fulvestrant
- Both companies will leverage their autologous CAR-T cell therapy programmes
- Ten23 health expands former swissfillon facility in Visp, Switzerland jkeenan Mon, 03/28/2022 - 08:41
- Sobi to trim staff as Pfizer manufacturing contract ends early jkeenan Thu, 03/24/2022 - 08:40
- Epinephrine recall: Adamis pulls Symjepi injections for needle clogging risks aliu Wed, 03/23/2022 - 11:18
- Fujifilm makes yet another deal to jack up cell and gene therapy capacity kdunleavy Tue, 03/22/2022 - 21:13
- Takeda's Natpara relaunch bid falls flat as manufacturing concerns drag on jkeenan Tue, 03/22/2022 - 09:22